Royalty Pharma Plc Cl A (RPRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
Sales | 537,267 | 567,978 | 596,068 | 536,313 | 538,202 |
Gross Profit | 537,267 | 567,978 | 596,068 | 536,313 | 538,202 |
Operating Expenses | 267,637 | 641,752 | -16,828 | 384,871 | 289,362 |
Operating Income | 269,630 | -73,774 | 612,896 | 151,442 | 248,840 |
Interest Expense | 49,013 | 44,232 | 47,255 | 46,033 | 46,949 |
Other Income | -26,240 | 113,733 | 151,945 | 16,668 | 149,445 |
Pre-tax Income | 194,377 | -4,273 | 717,586 | 122,077 | 351,336 |
Net Income Continuous | 194,377 | -4,273 | 717,586 | 122,077 | 351,336 |
Minority Interests | 92,373 | -9,051 | 223,246 | 49,963 | 123,711 |
Net Income | $102,004 | $4,778 | $494,340 | $72,114 | $227,625 |
EPS Basic Total Ops | 0.23 | 0.01 | 1.11 | 0.16 | 0.51 |
EPS Basic Continuous Ops | 0.43 | -0.01 | 1.60 | 0.27 | 0.78 |
EPS Diluted Total Ops | 0.23 | 0.01 | 1.11 | 0.16 | 0.50 |
EPS Diluted Continuous Ops | 0.33 | -0.01 | 1.20 | 0.20 | 0.58 |
EPS Diluted Before Non-Recurring Items | 0.96 | 0.98 | 1.15 | 0.79 | 0.85 |
EBITDA(a) | $274,189 | $-69,425 | $617,737 | $156,453 | $254,163 |